AD-214 in Healthy Volunteers and Patients with ILD or CKD

Phase 1, randomised, double-blind trial of AD-214 in interstitial lung disease (ILD) and chronic kidney disease (CKD) (4 arms), sponsored by AdAlta. Primary endpoints: Incidence of adverse events related to treatment in healthy volunteers at 141 days and Incidence of adverse events related to treatment in patients with ILD or CKD at 57 days. Started Jul 2023; status: completed.